A detailed history of State Street Corp transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 1,211,476 shares of EWTX stock, worth $22.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,211,476
Previous 892,709 35.71%
Holding current value
$22.1 Million
Previous $9.77 Million 126.26%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$9.25 - $19.97 $2.95 Million - $6.37 Million
318,767 Added 35.71%
1,211,476 $22.1 Million
Q4 2023

Feb 14, 2024

BUY
$5.51 - $12.1 $575,513 - $1.26 Million
104,449 Added 13.25%
892,709 $9.77 Million
Q3 2023

Nov 14, 2023

BUY
$5.73 - $7.69 $228,558 - $306,738
39,888 Added 5.33%
788,260 $4.52 Million
Q2 2023

Aug 14, 2023

BUY
$5.71 - $10.29 $512,466 - $923,517
89,749 Added 13.63%
748,372 $5.8 Million
Q1 2023

May 15, 2023

BUY
$6.66 - $11.33 $393,625 - $669,636
59,103 Added 9.86%
658,623 $4.39 Million
Q4 2022

Feb 14, 2023

BUY
$7.58 - $11.08 $281,930 - $412,109
37,194 Added 6.61%
599,520 $5.36 Million
Q3 2022

Nov 15, 2022

BUY
$8.08 - $13.58 $303,824 - $510,635
37,602 Added 7.17%
562,326 $5.53 Million
Q2 2022

Aug 15, 2022

SELL
$5.67 - $9.87 $223,885 - $389,726
-39,486 Reduced 7.0%
524,724 $4.18 Million
Q1 2022

May 16, 2022

BUY
$9.1 - $18.97 $323,705 - $674,800
35,572 Added 6.73%
564,210 $5.47 Million
Q4 2021

Feb 14, 2022

BUY
$14.41 - $22.41 $4.75 Million - $7.39 Million
329,542 Added 165.52%
528,638 $8.08 Million
Q3 2021

Nov 15, 2021

BUY
$14.11 - $24.1 $304,691 - $520,415
21,594 Added 12.17%
199,096 $3.31 Million
Q2 2021

Aug 16, 2021

BUY
$21.33 - $30.25 $3.79 Million - $5.37 Million
177,502 New
177,502 $3.79 Million

Others Institutions Holding EWTX

About Edgewise Therapeutics, Inc.


  • Ticker EWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 63,171,700
  • Market Cap $1.15B
  • Description
  • Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...
More about EWTX
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.